Xenetic Biosciences Reports Q3 2025 Financials, Secures $3.9M in October Offering

Xenetic Biosciences reported a net loss of $0.5 million in Q3 2025, with R&D expenses increasing by 105.6% to $0.8 million due to manufacturing development efforts and pre-clinical research. G&A expenses rose by 9.3% to $0.8 million, mainly due to increased legal costs. The company secured $3.9 million in net proceeds from an October 2025 offering and continues to advance its DNase-based technology towards Phase 1 clinical development for pancreatic carcinoma and other solid tumors.